Skip to content

A prospective, multicenter, single-group, target-value clinical trial evaluating the efficacy and safety of implantable cardiac contractility regulation systems in the treatment of heart failure

A prospective, multicenter, single-group, target-value clinical trial evaluating the efficacy and safety of implantable cardiac contractility regulation systems in the treatment of heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093203
Enrollment
Unknown
Registered
2024-11-29
Start date
2024-01-03
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with heart failure who have sinus rhythm or atrial fibrillation, a left ventricular ejection fraction (LVEF) of 25% <= LVEF <= 45%, and a persistent NYHA Class ? to ? despite optimal medical therapy (refractory to medical treatment)

Interventions

Single arm:The management of heart failure utilizing an implantable system for regulating systolic force

Sponsors

Hefei Gaoxin Cardiovascular Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged between 18 and 80 years old (including 18 and 80 years old), regardless of gender; 2. with heart failure of NYHA Class ? to ? persistently, despite receiving guideline-directed medical therapy (GDMT) for at least 90 days; 3. 25% <= LVEF <= 45%; 4. QRS duration < 130ms; 5. Good compliance, voluntary participation and signing of the subject informed consent, and regular follow-up.

Exclusion criteria

Exclusion criteria: 1. Have been implanted with CRT or have CRT indications; 2. Subjects with potentially correctable causes of heart failure, such as valvular heart disease or congenital heart disease; 3. patients with tricuspid valve replacement; 4. Subjects with clinically significant angina, including angina in daily life (i.e., Canadian Cardiovascular Society (CCS) angina rating II or higher); 5. Participants who received intravenous injection of positive inotropic drugs (except levosimendan) within 30 days before enrollment; 6. Exercise tolerance is limited by illness other than heart failure or inability to participate in the 6-minute walk; 7. Subjects who have received a heart transplant; 8. Patients who do not have access to vascular access to implant leads; 9. Patients who are not considered suitable to participate in this clinical study by the investigator.

Design outcomes

Primary

MeasureTime frame
The change in left ventricular ejection fraction (LVEF) at 6 months after surgery.;

Secondary

MeasureTime frame
Heart function grade of NYHA;MLHFQ rating;Left Ventricular End-systolic Volume;6MWT, 6 minute walking test;NT-proBNP;LVEF, left ventricular ejection fraction;Mortality from all causes and rates of readmission for heart failure;

Countries

China

Contacts

Public ContactKejiang Cao

Hefei Gaoxin Cardiovascular Hospital

745702184@qq.com+86 188 5604 6100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026